Skip to main content

Site notifications

Notice for pembrolizumab (Merck Sharp & Dohme (Australia) Pty Ltd)

Active ingredients
pembrolizumab
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Concentrate for injection
Indication
Treatment of biliary tract cancer
Therapeutic area
Oncology